{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:27:48Z","timestamp":1793878068850,"version":"4.7.0"},"reference-count":434,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["1U19AI171401"],"award-info":[{"award-number":["1U19AI171401"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.chembiol.2024.03.008","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T10:37:22Z","timestamp":1713436642000},"page":"632-657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs"],"prefix":"10.1016","volume":"31","author":[{"given":"Sho","family":"Iketani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2024.03.008_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib6","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib11","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib15","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib16","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib17","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib18","article-title":"Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19","author":"Dougan","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.chembiol.2024.03.008_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac053","article-title":"Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2\/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019","volume":"9","author":"Streinu-Cercel","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib20","series-title":"Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-hospitalized COVID-19 Patients","author":"Biosciences","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 - Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib22","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.chembiol.2024.03.008_bib25","doi-asserted-by":"crossref","first-page":"8270","DOI":"10.1128\/jvi.70.12.8270-8276.1996","article-title":"Genetic correlates of in\u00a0vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor","volume":"70","author":"Condra","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/374569a0","article-title":"In\u00a0vivo emergence of HIV-1 variants resistant to multiple protease inhibitors","volume":"374","author":"Condra","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib27","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1128\/jvi.68.3.2016-2020.1994","article-title":"Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor","volume":"68","author":"Ho","year":"1994","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib28","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/infdis\/173.6.1379","article-title":"In\u00a0vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies","volume":"173","author":"Jacobsen","year":"1996","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1128\/jvi.69.2.701-706.1995","article-title":"Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor","volume":"69","author":"Markowitz","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib30","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nm0796-760","article-title":"Ordered accumulation of mutations in HIV protease confers resistance to ritonavir","volume":"2","author":"Molla","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib31","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1128\/jvi.68.3.1660-1666.1994","article-title":"Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy","volume":"68","author":"Richman","year":"1994","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.7326\/0003-4819-128-11-199806010-00008","article-title":"Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients","volume":"128","author":"Shafer","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib33","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.282.12.1135","article-title":"HIV-1 drug resistance in newly infected individuals","volume":"282","author":"Boden","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib34","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM199304223281605","article-title":"Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1","volume":"328","author":"Erice","year":"1993","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM199807303390504","article-title":"Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors","volume":"339","author":"Hecht","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib37","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","article-title":"Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir","volume":"226","author":"Margot","year":"2022","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib38","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in\u00a0vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib40","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3851\/IMP3149","article-title":"In\u00a0vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6","volume":"22","author":"Xu","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.chembiol.2024.03.008_bib42","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib43","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib44","first-page":"44","article-title":"High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season","volume":"55","year":"2006","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.chembiol.2024.03.008_bib45","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jama.2009.294","article-title":"Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States","volume":"301","author":"Dharan","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105281","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020","volume":"200","author":"Govorkova","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/irv.12534","article-title":"Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study","volume":"12","author":"Lina","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.chembiol.2024.03.008_bib48","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib49","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group","volume":"334","author":"Collier","year":"1996","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib50","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.7326\/0003-4819-124-12-199606150-00001","volume":"124","author":"D'Aquila","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib51","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","article-title":"Virological response after 6\u00a0week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study","volume":"385","author":"Kohli","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib52","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in\u00a0vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib53","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1473-3099(17)30476-0","article-title":"Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Beigel","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib54","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1473-3099(21)00469-2","article-title":"Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial","volume":"22","author":"Kumar","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00754-20","article-title":"Conserved Genomic Terminals of SARS-CoV-2 as Coevolving Functional Elements and Potential Therapeutic Targets","volume":"5","author":"Chan","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.chembiol.2024.03.008_bib56","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1038\/s41467-021-22905-7","article-title":"SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes","volume":"12","author":"Jungreis","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/v12040360","article-title":"Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins","volume":"12","author":"Srinivasan","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.chembiol.2024.03.008_bib58","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00496-21","article-title":"Genome-Wide Variation in Betacoronaviruses","volume":"95","author":"LaTourrette","year":"2021","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib59","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nmeth.3027","article-title":"Deep mutational scanning: a new style of protein science","volume":"11","author":"Fowler","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.chembiol.2024.03.008_bib60","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1038\/s41467-022-34506-z","article-title":"Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1","volume":"13","author":"Moulana","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add7221","article-title":"Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning","volume":"8","author":"Ouyang","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.chembiol.2024.03.008_bib62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1126\/science.abo7896","article-title":"Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution","volume":"377","author":"Starr","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib63","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010951","article-title":"Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains","volume":"18","author":"Starr","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.chembiol.2024.03.008_bib65","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cell.2023.02.001","article-title":"A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike","volume":"186","author":"Dadonaite","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib68","first-page":"521","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","author":"Cao","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib69","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.chom.2022.08.003","article-title":"Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites","volume":"30","author":"Iketani","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib70","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77433","article-title":"Comprehensive fitness landscape of SARS-CoV-2 M(pro) reveals insights into viral resistance mechanisms","volume":"11","author":"Flynn","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.chembiol.2024.03.008_bib71","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.chembiol.2024.03.008_bib72","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"Rambaut","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib73","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","article-title":"GISAID: Global initiative on sharing all influenza data - from vision to reality","volume":"22","author":"Shu","year":"2017","journal-title":"Euro Surveill."},{"key":"10.1016\/j.chembiol.2024.03.008_bib74","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.4049\/jimmunol.149.5.1779","article-title":"Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion","volume":"149","author":"Burkly","year":"1992","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib76","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.str.2010.09.017","article-title":"Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody","volume":"18","author":"Freeman","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.chembiol.2024.03.008_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e3182732746","article-title":"Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope","volume":"62","author":"Pace","year":"2013","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.chembiol.2024.03.008_bib78","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib79","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib80","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib81","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib82","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/infdis\/jiy285","article-title":"Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates","volume":"218","author":"Pascal","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib83","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2023.01.002","article-title":"Structure of the Inmazeb cocktail and resistance to Ebola virus escape","volume":"31","author":"Rayaprolu","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib84","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.chembiol.2024.03.008_bib85","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in\u00a0vitro and in\u00a0vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib86","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.chembiol.2024.03.008_bib87","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrmicro974","article-title":"Passive antibody therapy for infectious diseases","volume":"2","author":"Casadevall","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib88","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2024.03.008_bib89","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd1987","article-title":"Anti-infective monoclonal antibodies: perils and promise of development","volume":"5","author":"Reichert","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2024.03.008_bib90","series-title":"FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib91","series-title":"FDA Authorizes Bamlanivimab and Etesevimab Monoclonal Antibody Therapy for Post-exposure Prophylaxis (Prevention) for COVID-19","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib92","series-title":"Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib93","series-title":"Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib94","series-title":"Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity against Omicron Variant","year":"2022"},{"key":"10.1016\/j.chembiol.2024.03.008_bib95","article-title":"MDFS grants Marketing Authorization for COVID-19 treatment","author":"Ministry of Food and Drug Safety","year":"2021","journal-title":"Regkirona Inj"},{"key":"10.1016\/j.chembiol.2024.03.008_bib96","series-title":"Celltrion\u2019s Monoclonal Antibody Treatment Regdanvimab, Approved by the European Commission for the Treatment of COVID-19","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib97","series-title":"Antibody Combination Therapy Approved to Treat COVID-19","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib98","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.chom.2022.01.005","article-title":"SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape","volume":"30","author":"Cele","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib99","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.cell.2021.03.027","article-title":"SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms","volume":"184","author":"Clark","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib100","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/s41591-022-01882-4","article-title":"Drivers of adaptive evolution during chronic SARS-CoV-2 infections","volume":"28","author":"Harari","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib101","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMc2202861","article-title":"SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients","volume":"386","author":"Scherer","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib102","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1599","article-title":"SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency","volume":"16","author":"Li","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib104","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vead075","article-title":"SARS-CoV-2 infection in immunosuppression evolves sub-lineages which independently accumulate neutralization escape mutations","volume":"10","author":"Lustig","year":"2024","journal-title":"Virus Evol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib105","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00110-24","article-title":"SARS-CoV-2 evolution during prolonged infection in immunocompromised patients","volume":"15","author":"Marques","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.chembiol.2024.03.008_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009849","article-title":"Acute SARS-CoV-2 infections harbor limited within-host diversity and transmit via tight transmission bottlenecks","volume":"17","author":"Braun","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.chembiol.2024.03.008_bib107","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1126\/science.abg8663","article-title":"Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes","volume":"372","author":"Saad-Roy","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib108","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41564-021-01041-4","article-title":"Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California","volume":"7","author":"Servellita","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib109","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1038\/s41467-021-26602-3","article-title":"Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants","volume":"12","author":"Weigang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib110","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1038\/s41467-023-38867-x","article-title":"Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants","volume":"14","author":"Gonzalez-Reiche","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib111","series-title":"Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib112","series-title":"Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant","year":"2022"},{"key":"10.1016\/j.chembiol.2024.03.008_bib113","series-title":"FDA Updates Sotrovimab Emergency Use Authorization","year":"2022"},{"key":"10.1016\/j.chembiol.2024.03.008_bib114","series-title":"FDA Announces Bebtelovimab Is Not Currently Authorized in Any US Region","year":"2022"},{"key":"10.1016\/j.chembiol.2024.03.008_bib115","series-title":"FDA Announces Evusheld Is Not Currently Authorized for Emergency Use in the U.S","year":"2023"},{"key":"10.1016\/j.chembiol.2024.03.008_bib116","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib117","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib118","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib119","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1016\/j.cell.2021.06.002","article-title":"The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies","volume":"184","author":"Copin","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib120","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Group","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib121","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib122","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiac320","article-title":"Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19","volume":"227","author":"Somersan-Karakaya","year":"2022","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib123","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25411","article-title":"Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial","volume":"5","author":"Portal-Celhay","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.chembiol.2024.03.008_bib124","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19","volume":"385","author":"O'Brien","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib125","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial","volume":"327","author":"O'Brien","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib126","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S1473-3099(22)00416-9","article-title":"Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial","volume":"22","author":"Herman","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib127","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib128","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/s41467-023-37591-w","article-title":"Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient","volume":"14","author":"Jaki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib129","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1186\/s12879-023-08797-6","article-title":"Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study","volume":"23","author":"Shimazu","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib130","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00791-22","article-title":"Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts","volume":"10","author":"Ko","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.chembiol.2024.03.008_bib131","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib132","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib133","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib134","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41586-021-03720-y","article-title":"In\u00a0vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains","volume":"596","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.chom.2021.04.007","article-title":"Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization","volume":"29","author":"Wang","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib136","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib137","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41586-021-03908-2","article-title":"Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York","volume":"597","author":"Annavajhala","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib138","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01386-21","article-title":"B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies","volume":"12","author":"Zhou","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.chembiol.2024.03.008_bib139","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib140","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.abn8652","article-title":"Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement","volume":"375","author":"McCallum","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib141","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib142","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib143","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib144","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib145","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2022.01.019","article-title":"Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron","volume":"185","author":"Cui","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib146","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib147","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib148","doi-asserted-by":"crossref","DOI":"10.3390\/v14061334","article-title":"Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies","volume":"14","author":"Zhou","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.chembiol.2024.03.008_bib149","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.cell.2022.04.035","article-title":"Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike","volume":"185","author":"Yamasoba","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib150","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn8897","article-title":"Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529","volume":"376","author":"Zhou","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib151","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.chom.2022.05.001","article-title":"Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages","volume":"30","author":"Ai","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib152","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.chom.2022.04.017","article-title":"SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies","volume":"30","author":"Arora","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib153","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib154","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib156","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib157","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib158","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial","volume":"326","author":"Cohen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib159","article-title":"Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection","volume":"3","author":"Boucau","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib160","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1093\/cid\/ciab912","article-title":"A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load","volume":"75","author":"Dougan","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib161","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib162","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19","volume":"384","author":"Lundgren","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib163","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/M21-3507","article-title":"Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial","volume":"175","author":"Lundgren","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib164","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1038\/s41467-022-32551-2","article-title":"Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19","volume":"13","author":"Chew","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib165","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib166","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3390\/v13081642","article-title":"Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2","volume":"13","author":"Peiffer-Smadja","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.chembiol.2024.03.008_bib167","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41564-022-01254-1","article-title":"Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial","volume":"7","author":"Choudhary","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib168","article-title":"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany","volume":"8","author":"Jensen","year":"2021","journal-title":"Lancet Reg. Health. Eur."},{"key":"10.1016\/j.chembiol.2024.03.008_bib169","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/cid\/ciab392","article-title":"Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient","volume":"73","author":"Lohr","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib170","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166032","article-title":"Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments","volume":"133","author":"Gupta","year":"2023","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.chembiol.2024.03.008_bib171","doi-asserted-by":"crossref","first-page":"veac104","DOI":"10.1093\/ve\/veac104","article-title":"Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual","volume":"9","author":"Halfmann","year":"2023","journal-title":"Virus Evol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib172","doi-asserted-by":"crossref","DOI":"10.1177\/13596535221097495","article-title":"Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection","volume":"29","author":"Boussen","year":"2024","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.chembiol.2024.03.008_bib173","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3201\/eid2710.211538","article-title":"Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19","volume":"27","author":"Focosi","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib174","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jinf.2021.08.033","article-title":"Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab\/etesevimab treatment and resistance to viral clearance","volume":"84","author":"Guigon","year":"2022","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.chembiol.2024.03.008_bib175","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1126\/science.abi7994","article-title":"SARS-CoV-2 immune evasion by the B.1.427\/B.1.429 variant of concern","volume":"373","author":"McCallum","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib176","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109825","article-title":"B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination","volume":"37","author":"Arora","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2024.03.008_bib178","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib179","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib180","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.20957","article-title":"Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial","volume":"5","author":"Huang","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.chembiol.2024.03.008_bib181","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(21)00751-9","article-title":"Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial","volume":"22","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib182","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41586-021-03807-6","article-title":"SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape","volume":"597","author":"Starr","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib183","article-title":"The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in\u00a0vitro and in\u00a0vivo activity against SARS-CoV-2","author":"Cathcart","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.chembiol.2024.03.008_bib184","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.966236","article-title":"Targeted escape of SARS-CoV-2 in\u00a0vitro from monoclonal antibody S309, the precursor of sotrovimab","volume":"13","author":"Magnus","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib185","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cmi.2022.08.021","article-title":"Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion","volume":"29","author":"Andr\u00e9s","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.chembiol.2024.03.008_bib186","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jama.2022.13854","article-title":"Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant","volume":"328","author":"Birnie","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00120-3","article-title":"Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients","volume":"3","author":"Destras","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib188","article-title":"Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases","volume":"2","author":"Focosi","year":"2022","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib189","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/cid\/ciac802","article-title":"Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients","volume":"76","author":"Gliga","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib190","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1093\/cid\/ciac601","article-title":"Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant","volume":"76","author":"Huygens","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib191","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use","volume":"386","author":"Rockett","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib192","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cmi.2022.05.002","article-title":"Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab","volume":"28","author":"Vellas","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.chembiol.2024.03.008_bib193","article-title":"SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses","volume":"3","author":"Mazzetti","year":"2023","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib194","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00266-23","article-title":"Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab","volume":"67","author":"Palomino-Cabrera","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib195","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.medj.2023.08.001","article-title":"Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2","volume":"4","author":"Hirotsu","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.chembiol.2024.03.008_bib196","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/IDR.S438915","article-title":"Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient","volume":"17","author":"Tanino","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.chembiol.2024.03.008_bib197","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib198","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1038\/s41467-022-31615-7","article-title":"Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains","volume":"13","author":"Case","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib199","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","article-title":"Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2","volume":"607","author":"Uraki","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jinf.2023.02.012","article-title":"Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study","volume":"86","author":"Evans","year":"2023","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.chembiol.2024.03.008_bib201","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.jinf.2022.06.033","article-title":"Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2","volume":"85","author":"Martin-Blondel","year":"2022","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.chembiol.2024.03.008_bib202","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(22)01938-9","article-title":"WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed","volume":"400","author":"Wu","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib203","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib204","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41564-021-00972-2","article-title":"Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail","volume":"6","author":"Dong","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib205","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib206","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib207","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S2213-2600(22)00215-6","article-title":"Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial","volume":"10","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib208","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10039","article-title":"Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials","volume":"6","author":"Bender Ignacio","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.chembiol.2024.03.008_bib209","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/cid\/ciac899","article-title":"AZD7442 (Tixagevimab\/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19","volume":"76","author":"Levin","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib210","series-title":"Evusheld Long-Acting Antibody Combination Approved for Prevention and Treatment of COVID-19 in Japan","year":"2022"},{"key":"10.1016\/j.chembiol.2024.03.008_bib211","series-title":"Evusheld Long-Acting Antibody Combination Approved in the EU for the Treatment of COVID-19","year":"2022"},{"key":"10.1016\/j.chembiol.2024.03.008_bib212","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1016\/j.jinf.2022.07.014","article-title":"Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment","volume":"85","author":"Vellas","year":"2022","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.chembiol.2024.03.008_bib213","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/s41564-022-01170-4","article-title":"Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters","volume":"7","author":"Uraki","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib214","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1473-3099(22)00831-3","article-title":"Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage","volume":"23","author":"Arora","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib216","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","article-title":"Omicron sublineage BQ.1.1 resistance to monoclonal antibodies","volume":"23","author":"Arora","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib217","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc2214302","article-title":"Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB","volume":"388","author":"Imai","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib218","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41467-023-36561-6","article-title":"Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies","volume":"14","author":"Planas","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2024.03.008_bib220","doi-asserted-by":"crossref","first-page":"e28565","DOI":"10.1002\/jmv.28565","article-title":"Concerns on Bebtelovimab (LY-CoV1404) used to neutralize Omicron subvariants","volume":"95","author":"Wang","year":"2023","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib221","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1473-3099(22)00422-4","article-title":"Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5","volume":"22","author":"Arora","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib222","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1056\/NEJMc2211845","article-title":"In\u00a0Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6","volume":"387","author":"Takashita","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib223","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib224","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(22)00365-6","article-title":"Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies","volume":"22","author":"Yamasoba","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib225","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.chom.2022.07.002","article-title":"SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns","volume":"30","author":"Gruell","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib226","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.chom.2022.09.002","article-title":"Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75","volume":"30","author":"Wang","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib227","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.chom.2022.09.018","article-title":"Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75","volume":"30","author":"Cao","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib228","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S1473-3099(22)00591-6","article-title":"Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75","volume":"22","author":"Arora","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib229","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S1473-3099(22)00580-1","article-title":"Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage","volume":"22","author":"Gruell","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib230","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJMc2209952","article-title":"Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75","volume":"387","author":"Takashita","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib231","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.chom.2022.10.003","article-title":"Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant","volume":"30","author":"Saito","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib232","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41467-020-20602-5","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib233","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.clinthera.2021.08.009","volume":"43","author":"Kim","year":"2021","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.chembiol.2024.03.008_bib234","article-title":"A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019","volume":"9","author":"Kim","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2021.06.016","article-title":"Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant","volume":"566","author":"Ryu","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib236","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbrc.2021.09.023","article-title":"The in\u00a0vitro and in\u00a0vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2","volume":"578","author":"Ryu","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib237","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib238","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.immuni.2021.06.003","article-title":"Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species","volume":"54","author":"Wang","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.chembiol.2024.03.008_bib239","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.980435","article-title":"Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2","volume":"13","author":"Ji","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib240","doi-asserted-by":"crossref","first-page":"S807","DOI":"10.1093\/ofid\/ofab466.1643","article-title":"LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients","volume":"8","author":"Evering","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib241","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M22-3428","article-title":"Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19","volume":"176","author":"Evering","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib242","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41467-020-20501-9","article-title":"Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry","volume":"12","author":"Ge","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib243","article-title":"SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib244","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib245","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved Antiviral Drugs over the Past 50 Years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.chembiol.2024.03.008_bib246","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1039\/C4NP00085D","article-title":"Antiviral drug discovery: broad-spectrum drugs from nature","volume":"32","author":"Martinez","year":"2015","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.chembiol.2024.03.008_bib247","series-title":"FDA Approves First Treatment for COVID-19","year":"2020"},{"key":"10.1016\/j.chembiol.2024.03.008_bib248","series-title":"Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib249","series-title":"Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults","year":"2021"},{"key":"10.1016\/j.chembiol.2024.03.008_bib250","series-title":"\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u6cbb\u7642\u85ac\u306e\u7dca\u6025\u627f\u8a8d\u306b\u3064\u3044\u3066","year":"2022"},{"key":"10.1016\/j.chembiol.2024.03.008_bib251","series-title":"Xocova\u00ae (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System","year":"2022"},{"key":"10.1016\/j.chembiol.2024.03.008_bib252","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V'Kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib253","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/acsmedchemlett.1c00624","article-title":"Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2","volume":"13","author":"Mackman","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.chembiol.2024.03.008_bib254","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","article-title":"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV","volume":"64","author":"Mackman","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2024.03.008_bib255","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib256","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f] [triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2024.03.008_bib257","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/cid\/ciab215","article-title":"PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors","volume":"73","author":"Higgs","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib258","doi-asserted-by":"crossref","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-Pneumo-and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2024.03.008_bib259","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/infdis\/jiaa290","article-title":"Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus","volume":"222","author":"Porter","year":"2020","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104899","article-title":"Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses","volume":"182","author":"Konkolova","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib261","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006889","article-title":"Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase","volume":"14","author":"Jordan","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.chembiol.2024.03.008_bib262","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau9242","article-title":"Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge","volume":"11","author":"Lo","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib263","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3389\/fmicb.2020.01105","article-title":"Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition","volume":"11","author":"Ye","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib264","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib265","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vetmic.2018.04.026","article-title":"The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies","volume":"219","author":"Murphy","year":"2018","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib266","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1098612X19825701","article-title":"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis","volume":"21","author":"Pedersen","year":"2019","journal-title":"J.\u00a0Feline Med. Surg."},{"key":"10.1016\/j.chembiol.2024.03.008_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib268","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib269","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.chembiol.2024.03.008_bib270","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib271","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2024.03.008_bib272","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1021\/acs.jmedchem.0c01929","article-title":"Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models","volume":"65","author":"Li","year":"2022","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2024.03.008_bib273","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1038\/s41467-021-26760-4","article-title":"Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets","volume":"12","author":"Cox","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib274","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105329","article-title":"Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection","volume":"203","author":"Pitts","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib275","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib276","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109450","article-title":"Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice","volume":"36","author":"Martinez","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2024.03.008_bib277","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8282","article-title":"Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection","volume":"14","author":"Vermillion","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib278","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm3410","article-title":"Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice","volume":"14","author":"Sch\u00e4fer","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib279","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105246","article-title":"Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2","volume":"198","author":"Williamson","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib280","article-title":"Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model","volume":"13","author":"Chiba","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.chembiol.2024.03.008_bib281","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2024.03.008_bib282","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.molcel.2021.01.035","article-title":"Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication","volume":"81","author":"Bravo","year":"2021","journal-title":"Mol. Cell."},{"key":"10.1016\/j.chembiol.2024.03.008_bib283","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib284","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib285","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib286","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib287","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial","volume":"194","author":"Ali","year":"2022","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.chembiol.2024.03.008_bib288","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib289","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results","volume":"384","author":"Pan","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib290","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.7326\/M21-0653","article-title":"Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial","volume":"174","author":"Barratt-Due","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib291","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib292","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib293","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00222-22","article-title":"Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants","volume":"66","author":"Pitts","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib294","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib295","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105609","article-title":"Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants","volume":"214","author":"Cho","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib296","article-title":"A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance","volume":"14","author":"Grimes","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.chembiol.2024.03.008_bib297","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo0718","article-title":"Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms","volume":"14","author":"Stevens","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib298","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00198-22","article-title":"In\u00a0Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance","volume":"66","author":"Checkmahomed","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib299","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009929","article-title":"In\u00a0vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2","volume":"17","author":"Szemiel","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.chembiol.2024.03.008_bib300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011231","article-title":"Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir","volume":"19","author":"Torii","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.chembiol.2024.03.008_bib301","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105840","article-title":"The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance","volume":"225","author":"Schreiber","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib302","article-title":"Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection","volume":"3","author":"Heyer","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib303","doi-asserted-by":"crossref","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","article-title":"Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019","volume":"73","author":"Martinot","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib304","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/cid\/ciac769","article-title":"Remdesivir Resistance in Transplant Recipients With Persistent Coronavirus Disease 2019","volume":"76","author":"Hogan","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib305","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/infdis\/jiad270","article-title":"Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)","volume":"228","author":"Hedskog","year":"2023","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib306","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib307","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib308","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2024.03.008_bib309","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib310","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01819-20","article-title":"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL(pro) inhibitor PF-00835231 as a potential new treatment for COVID-19","volume":"95","author":"de Vries","year":"2021","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib311","doi-asserted-by":"crossref","first-page":"18422","DOI":"10.1073\/pnas.1010693107","article-title":"Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir","volume":"107","author":"Sevrioukova","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib312","article-title":"Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study","volume":"33","author":"Liu","year":"2023","journal-title":"Lancet Reg. Health. West. Pac."},{"key":"10.1016\/j.chembiol.2024.03.008_bib313","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib314","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41467-022-28354-0","article-title":"The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern","volume":"13","author":"Abdelnabi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128629","article-title":"Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir","volume":"62","author":"Ullrich","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.chembiol.2024.03.008_bib316","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101972","article-title":"Structural basis for the in\u00a0vitro efficacy of nirmatrelvir against SARS-CoV-2 variants","volume":"298","author":"Greasley","year":"2022","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2024.03.008_bib317","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1021\/acs.biochem.3c00075","article-title":"Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants","volume":"62","author":"Jiang","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.chembiol.2024.03.008_bib318","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s42003-023-05071-y","article-title":"Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants","volume":"6","author":"Lin","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib319","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib320","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.chembiol.2024.03.008_bib321","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105671","article-title":"Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors","volume":"216","author":"Takashita","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib322","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105814","article-title":"Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains","volume":"222","author":"Bouzidi","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib323","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02815-22","article-title":"The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In\u00a0Vitro and Confer Resistance To Nirmatrelvir","volume":"14","author":"Jochmans","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.chembiol.2024.03.008_bib324","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1038\/s41467-023-39704-x","article-title":"In\u00a0vitro and in\u00a0vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir","volume":"14","author":"Kiso","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib325","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41467-023-37773-6","article-title":"Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment","volume":"14","author":"Abdelnabi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib326","article-title":"Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies","author":"Lan","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.chembiol.2024.03.008_bib327","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s44259-023-00009-0","article-title":"Rapid resistance profiling of SARS-CoV-2 protease inhibitors","volume":"1","author":"Moghadasi","year":"2023","journal-title":"npj Antimicrob. Resist."},{"key":"10.1016\/j.chembiol.2024.03.008_bib328","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103004","article-title":"Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 Main Protease","volume":"299","author":"Noske","year":"2023","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2024.03.008_bib329","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8778","article-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors","volume":"9","author":"Moghadasi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.chembiol.2024.03.008_bib330","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.chembiol.2024.03.008_bib331","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011592","article-title":"A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations","volume":"19","author":"Ou","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.chembiol.2024.03.008_bib332","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1021\/acs.jcim.3c00344","article-title":"An Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease","volume":"63","author":"Clayton","year":"2023","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.chembiol.2024.03.008_bib333","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq7360","article-title":"SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376","volume":"15","author":"Heilmann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib334","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1021\/acs.biochem.2c00489","article-title":"Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening","volume":"61","author":"Sasi","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.chembiol.2024.03.008_bib335","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/cid\/ciad494","article-title":"Nirmatrelvir resistance - de novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure - a case report","volume":"78","author":"Zuckerman","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib336","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","article-title":"Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir","volume":"622","author":"Duan","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib337","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","article-title":"Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19","volume":"50","author":"Painter","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib338","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","article-title":"Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture","volume":"47","author":"Stuyver","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib339","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3851\/IMP2229","article-title":"Antiviral activity of nucleoside analogues against norovirus","volume":"17","author":"Costantini","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.chembiol.2024.03.008_bib340","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.3390\/v7122934","article-title":"Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication","volume":"7","author":"Reynard","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.chembiol.2024.03.008_bib341","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02395-16","article-title":"Characterization of beta-d-N(4)-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus","volume":"61","author":"Ehteshami","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib342","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01965-17","article-title":"beta-d-N(4)-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome","volume":"92","author":"Urakova","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib343","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104597","article-title":"The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection","volume":"171","author":"Painter","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib344","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib345","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib346","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/095632020401500102","article-title":"Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine","volume":"15","author":"Barnard","year":"2004","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib347","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/AAC.01598-05","article-title":"Inhibition of human coronavirus NL63 infection at early stages of the replication cycle","volume":"50","author":"Pyrc","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib348","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01348-19","article-title":"Small-Molecule Antiviral beta-d-N(4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib349","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib350","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib351","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib352","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","volume":"297","author":"Gordon","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2024.03.008_bib353","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib354","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib355","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.7326\/M22-0729","article-title":"Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial","volume":"175","author":"Johnson","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib356","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s15010-022-01959-9","article-title":"Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial","volume":"51","author":"Johnson","year":"2023","journal-title":"Infection"},{"key":"10.1016\/j.chembiol.2024.03.008_bib357","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1473-3099(22)00644-2","article-title":"Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"23","author":"Khoo","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib358","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2024.03.008_bib359","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160108","article-title":"Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model","volume":"7","author":"Rosenke","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.chembiol.2024.03.008_bib360","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1038\/s41467-022-32045-1","article-title":"SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model","volume":"13","author":"Lieber","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib361","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.231","article-title":"153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in\u00a0vitro","volume":"9","author":"Strizki","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib362","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00953-23","article-title":"Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance","volume":"68","author":"Strizki","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib363","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.1038\/s41467-022-34839-9","article-title":"Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial","volume":"13","author":"Donovan-Banfield","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib364","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41467-024-45641-0","article-title":"Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients","volume":"15","author":"Standing","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib365","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2024.03.008_bib366","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkad027","article-title":"Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in\u00a0vitro and in\u00a0vivo","volume":"78","author":"Kuroda","year":"2023","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib367","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/jac\/dkac257","article-title":"Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model","volume":"77","author":"Nobori","year":"2022","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib368","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4064","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib369","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A Randomized Phase 2\/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2024.03.008_bib370","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study","volume":"76","author":"Mukae","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib371","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2023.01.040","article-title":"Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally","volume":"645","author":"Kawashima","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib372","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1038\/s41467-023-40018-1","article-title":"In\u00a0vitro and in\u00a0vivo characterization of SARS-CoV-2 resistance to ensitrelvir","volume":"14","author":"Kiso","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.03.008_bib373","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00089-23","article-title":"Virology under the Microscope-a Call for Rational Discourse","volume":"97","author":"Goodrum","year":"2023","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib374","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41586-021-03792-w","article-title":"After the pandemic: perspectives on the future trajectory of COVID-19","volume":"596","author":"Telenti","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib375","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a Fourth Dose of BNT162b2 against Omicron in Israel","volume":"386","author":"Bar-On","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib376","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJMc2214114","article-title":"Protection against Reinfection with the Omicron BA.2.75 Subvariant","volume":"388","author":"Chemaitelly","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib377","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMc2210093","article-title":"Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa","volume":"387","author":"Collie","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib378","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2215471","article-title":"Effectiveness of Bivalent Boosters against Severe Omicron Infection","volume":"388","author":"Lin","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib379","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra2206573","article-title":"Covid-19 Vaccines - Immunity, Variants, Boosters","volume":"387","author":"Barouch","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib380","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib381","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMp2215780","article-title":"Bivalent Covid-19 Vaccines - A Cautionary Tale","volume":"388","author":"Offit","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib382","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13906","article-title":"Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS-CoV-2 in the endemic phase?","volume":"53","author":"Pilz","year":"2023","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.chembiol.2024.03.008_bib383","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-023-02228-4","article-title":"Predicting the efficacy of variant-modified COVID-19 vaccine boosters","volume":"29","author":"Khoury","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib384","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.chembiol.2024.03.008_bib385","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.chembiol.2024.03.008_bib386","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2214-109X(21)00593-3","article-title":"Response to\u00a0additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review","volume":"10","author":"Parker","year":"2022","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.chembiol.2024.03.008_bib387","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111798","article-title":"Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients","volume":"13","author":"Weichseldorfer","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.chembiol.2024.03.008_bib388","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000600","article-title":"Broadly neutralizing antibodies for the treatment and prevention of HIV infection","volume":"15","author":"Caskey","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.chembiol.2024.03.008_bib389","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01847-22","article-title":"Virology in Peril and the Greater Risk To Science","volume":"97","author":"Imperiale","year":"2023","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib390","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1126\/science.abk0029","article-title":"Create a COVID-19 commission","volume":"374","author":"Chyba","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib391","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/s41591-022-02054-0","article-title":"Data-enabled responses to pandemics: policy lessons from COVID-19","volume":"28","author":"Dhami","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib392","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1126\/science.abc3189","article-title":"Ecology and economics for pandemic prevention","volume":"369","author":"Dobson","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib393","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1126\/science.abb9342","article-title":"Policy opportunities to enhance sharing for pandemic research","volume":"368","author":"Rourke","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib394","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/d41586-022-01312-y","article-title":"Want to prevent pandemics? Stop spillovers","volume":"605","author":"Vora","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib395","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/435421a","article-title":"Is China prepared for microbial threats?","volume":"435","author":"Ho","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib396","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001935","article-title":"Developing Global Norms for Sharing Data and Results during Public Health Emergencies","volume":"13","author":"Modjarrad","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib397","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1056\/NEJMsr1813907","article-title":"Pathogen Genomics in Public Health","volume":"381","author":"Armstrong","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib398","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025791","article-title":"Next-Generation Sequencing Strategies","volume":"9","author":"Levy","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib399","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41588-022-01033-y","article-title":"Global landscape of SARS-CoV-2 genomic surveillance and data sharing","volume":"54","author":"Chen","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.chembiol.2024.03.008_bib400","doi-asserted-by":"crossref","first-page":"e1240","DOI":"10.1016\/S2214-109X(22)00319-9","article-title":"Simple and structured model to build sequencing capacity in west Africa","volume":"10","author":"Kanteh","year":"2022","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.chembiol.2024.03.008_bib401","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S1473-3099(22)00723-X","article-title":"Advancing detection and response capacities for emerging and re-emerging pathogens in Africa","volume":"23","author":"Nachega","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib402","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-021-01327-4","article-title":"Africa needs more genome sequencing to tackle new variants of SARS-CoV-2","volume":"27","author":"Otu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib403","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41591-022-01836-w","article-title":"An early warning system for emerging SARS-CoV-2 variants","volume":"28","author":"Subissi","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib404","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq5358","article-title":"The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance","volume":"378","author":"Tegally","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.03.008_bib405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002225","article-title":"Towards a post-pandemic future for global pathogen genome sequencing","volume":"21","author":"Ladner","year":"2023","journal-title":"PLoS Biol."},{"key":"10.1016\/j.chembiol.2024.03.008_bib406","doi-asserted-by":"crossref","first-page":"D121","DOI":"10.1093\/nar\/gkaa967","article-title":"The international nucleotide sequence database collaboration","volume":"49","author":"Arita","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib407","doi-asserted-by":"crossref","first-page":"D134","DOI":"10.1093\/nar\/gkad903","article-title":"GenBank 2024\u00a0Update","volume":"52","author":"Sayers","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib408","doi-asserted-by":"crossref","first-page":"D101","DOI":"10.1093\/nar\/gkac1083","article-title":"DNA Data Bank of Japan (DDBJ) update report 2022","volume":"51","author":"Tanizawa","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib409","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1093\/nar\/gkad1067","article-title":"The European Nucleotide Archive in 2023","volume":"52","author":"Yuan","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chembiol.2024.03.008_bib410","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.chembiol.2024.03.008_bib411","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00926-22","article-title":"Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis","volume":"10","author":"Tao","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.chembiol.2024.03.008_bib412","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nmeth.2918","article-title":"Large-scale de novo DNA synthesis: technologies and applications","volume":"11","author":"Kosuri","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.chembiol.2024.03.008_bib413","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Estimating the cost of new drug development: is it really 802 million dollars?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Aff."},{"key":"10.1016\/j.chembiol.2024.03.008_bib414","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.chembiol.2024.03.008_bib415","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases","volume":"451","author":"Jones","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib416","doi-asserted-by":"crossref","DOI":"10.1038\/srep14830","article-title":"Spillover and pandemic properties of zoonotic viruses with high host plasticity","volume":"5","author":"Kreuder Johnson","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2024.03.008_bib417","doi-asserted-by":"crossref","DOI":"10.3390\/v15010199","article-title":"Which Virus Will Cause the Next Pandemic?","volume":"15","author":"Neumann","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.chembiol.2024.03.008_bib418","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature22975","article-title":"Host and viral traits predict zoonotic spillover from mammals","volume":"546","author":"Olival","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib419","series-title":"NIAID Announces Antiviral Drug Development Awards","year":"2022"},{"key":"10.1016\/j.chembiol.2024.03.008_bib420","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2214-109X(20)30542-8","article-title":"How COVID-19 has fundamentally changed clinical research in global health","volume":"9","author":"Park","year":"2021","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.chembiol.2024.03.008_bib421","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41591-021-01617-x","article-title":"Clinical trial design during and beyond the pandemic: the I-SPY COVID trial","volume":"28","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib422","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jama.2023.11043","article-title":"Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial","volume":"330","author":"O'Halloran","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib423","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1093\/infdis\/jiad209","article-title":"Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial","volume":"228","author":"Moser","year":"2023","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2024.03.008_bib424","article-title":"The mRNA vaccine revolution is the dividend from decades of basic science research","volume":"131","author":"Casadevall","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.chembiol.2024.03.008_bib425","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib426","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-012621-102252","article-title":"COVID-19 Vaccines: Adenoviral Vectors","volume":"73","author":"Jacob-Dolan","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.chembiol.2024.03.008_bib427","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.chembiol.2024.03.008_bib428","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development - Progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.chembiol.2024.03.008_bib429","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41586-020-2562-8","article-title":"Zoonotic host diversity increases in human-dominated ecosystems","volume":"584","author":"Gibb","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib430","doi-asserted-by":"crossref","first-page":"8399","DOI":"10.1073\/pnas.1208059110","article-title":"Zoonosis emergence linked to agricultural intensification and environmental change","volume":"110","author":"Jones","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2024.03.008_bib431","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nature09575","article-title":"Impacts of biodiversity on the emergence and transmission of infectious diseases","volume":"468","author":"Keesing","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib432","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-022-04788-w","article-title":"Climate change increases cross-species viral transmission risk","volume":"607","author":"Carlson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.03.008_bib433","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","volume":"13","author":"Zhao","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.chembiol.2024.03.008_bib434","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945624001247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945624001247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:20:20Z","timestamp":1762626020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945624001247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":434,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2451945624001247"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2024.03.008","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2024.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}